<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22903">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808624</url>
  </required_header>
  <id_info>
    <org_study_id>PT(1451)</org_study_id>
    <nct_id>NCT02808624</nct_id>
  </id_info>
  <brief_title>L-carnosine Prophylactic Effect on Oxaliplatin Induced Peripheral Neuropathy in GIT Cancer Patients</brief_title>
  <official_title>The Potential Prophylactic Effect of Exogenous Antioxidant ''L-CARNOSINE'' on Oxaliplatin-induced Peripheral Neuropathy in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Misr International University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the prophylactic effect of exogenous L-CARNOSINE in Oxaliplatin induced
      peripheral neuropathy, Thus half of the patients will receive L-CARNOSINE with Oxaliplatin
      and the other half will not receive L-CARNOSINE with their chemotherapy (oxaliplatin),And
      then neuropathy together with some oxidative stress markers will be assessed at the end of
      treatment duration (three months) .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxaliplatin causes peripheral neuropathy , L-CARNOSINE is supposed to prevent this side
      effect possibly by reducing oxidative stress and enhancing the growth of nerves.This study
      is intended to clarify the effect and mechanism of action of L-CARNOSINE in preventing
      Oxaliplatin induced peripheral neuropathy in cancer patients.

      Blood samples will be collected from the patients before starting the chemotherapy and at
      the end of treatment duration (3 months) and then oxidative stress markers will be measured
      in these samples
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of peripheral neuropathy using neuropathy grading score &quot;CTCAE&quot;, version 4.0) also oxidative stress markers will be measured by ELISA kits.</measure>
    <time_frame>Three months</time_frame>
    <description>The following markers will be measured by ELISA kits :
Nrf2 induced oxidative stress pathways (GSH) NF-KB anti-inflammatory pathway (TNF- alpha) pro-apoptic signals (caspase 3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of tumor markers (CA,CEA) in blood.</measure>
    <time_frame>Three months</time_frame>
    <description>Tumor Markers (CA,CEA) will be assessed at the end of treatment duration to make sure that L-CARNOSINE didn't interfere with the patients' response to chemotherapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Peripheral Neuropathy</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>this arm will receive L-CARNOSINE PO BID (each patient will receive 2 tablets daily and each tablet contains 500 mg thus a total of 1000 mg per day) together with their chemotherapy wich is oxaliplatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm wont receive L-CARNOSINE, they will receive their chemotherapy (oxaliplatin) only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-CARNOSINE</intervention_name>
    <description>L-CARNOSINE is a supplement given with chemotherapy to prevent peripheral neuropathy.</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>CARNOSINE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients are eligible to be enrolled in this study, if they meet the following criteria

          1. Elderly males and females with age (˃18 and ˂60).

          2. Cancer patients treated with oxaliplatin for the first time (dose 85- 135mg/m2)
             administered every two to three weeks for 3 months.

        Exclusion Criteria:

        Excluded from this study are the patients with the following Criteria:

          -  Suffering from diabetes mellitus.

          -  Suffering from peripheral neuropathy as a result of any other disease or drug.

          -  Suffering from severe renal impairment (CrCl ˂ 30 ml/min).

          -  Suffering from epilepsy.

          -  Taking vitamin B.

          -  Who previously took Oxaliplatin or any other chemotherapeutic agent that causes
             peripheral neuropathy.

          -  Taking antidepressants or MAOI's.

          -  Taking NSAIDs, paracetamol, opiates or any other analgesics or pain killers.

          -  Pregnant or lactating patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rana Yehia, B.PHARM</last_name>
    <phone>01006666652</phone>
    <email>Rana.Magdy@miuegypt.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amr Shafik, MD</last_name>
    <phone>01227888314</phone>
    <email>docshak76@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <state>Kasr el Aini</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rana Yehia, B.PHARM</last_name>
      <phone>01006666652</phone>
      <email>rana.magdy@miuegypt.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Amr Shafik, MD</last_name>
      <phone>01227888314</phone>
      <email>docshak76@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rana yehia, B.PHARM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 2, 2016</lastchanged_date>
  <firstreceived_date>May 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Rana Magdy</investigator_full_name>
    <investigator_title>Teaching assistant</investigator_title>
  </responsible_party>
  <keyword>Oxaliplatin, peripheral neuropathy, L-CARNOSINE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
